Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney AY, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.

Cancer Immunol Res. 2019 Oct;7(10):1633-1646. doi: 10.1158/2326-6066.CIR-18-0579. Epub 2019 Aug 20.

PMID:
31431433
2.

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, Roccaro A, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM.

Mol Cancer Ther. 2018 Jul;17(7):1454-1463. doi: 10.1158/1535-7163.MCT-17-0998. Epub 2018 Apr 13.

3.

PD-1 blockade enhances elotuzumab efficacy in mouse tumor models.

Bezman NA, Jhatakia A, Kearney AY, Brender T, Maurer M, Henning K, Jenkins MR, Rogers AJ, Neeson PJ, Korman AJ, Robbins MD, Graziano RF.

Blood Adv. 2017 May 8;1(12):753-765. doi: 10.1182/bloodadvances.2017004382. eCollection 2017 May 9.

4.

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.

Pazina T, James AM, MacFarlane AW 4th, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS.

Oncoimmunology. 2017 Jun 16;6(9):e1339853. doi: 10.1080/2162402X.2017.1339853. eCollection 2017.

5.

Proapoptotic Bim regulates antigen-specific NK cell contraction and the generation of the memory NK cell pool after cytomegalovirus infection.

Min-Oo G, Bezman NA, Madera S, Sun JC, Lanier LL.

J Exp Med. 2014 Jun 30;211(7):1289-96. doi: 10.1084/jem.20132459. Epub 2014 Jun 23.

6.

The transcriptional landscape of αβ T cell differentiation.

Mingueneau M, Kreslavsky T, Gray D, Heng T, Cruse R, Ericson J, Bendall S, Spitzer MH, Nolan GP, Kobayashi K, von Boehmer H, Mathis D, Benoist C; Immunological Genome Consortium, Best AJ, Knell J, Goldrath A, Joic V, Koller D, Shay T, Regev A, Cohen N, Brennan P, Brenner M, Kim F, Nageswara Rao T, Wagers A, Heng T, Ericson J, Rothamel K, Ortiz-Lopez A, Mathis D, Benoist C, Bezman NA, Sun JC, Min-Oo G, Kim CC, Lanier LL, Miller J, Brown B, Merad M, Gautier EL, Jakubzick C, Randolph GJ, Monach P, Blair DA, Dustin ML, Shinton SA, Hardy RR, Laidlaw D, Collins J, Gazit R, Rossi DJ, Malhotra N, Sylvia K, Kang J, Kreslavsky T, Fletcher A, Elpek K, Bellemare-Pelletier A, Malhotra D, Turley S.

Nat Immunol. 2013 Jun;14(6):619-32. doi: 10.1038/ni.2590. Epub 2013 May 5.

7.

Identification of transcriptional regulators in the mouse immune system.

Jojic V, Shay T, Sylvia K, Zuk O, Sun X, Kang J, Regev A, Koller D; Immunological Genome Project Consortium, Best AJ, Knell J, Goldrath A, Joic V, Koller D, Shay T, Regev A, Cohen N, Brennan P, Brenner M, Kim F, Rao TN, Wagers A, Heng T, Ericson J, Rothamel K, Ortiz-Lopez A, Mathis D, Benoist C, Bezman NA, Sun JC, Min-Oo G, Kim CC, Lanier LL, Miller J, Brown B, Merad M, Gautier EL, Jakubzick C, Randolph GJ, Monach P, Blair DA, Dustin ML, Shinton SA, Hardy RR, Laidlaw D, Collins J, Gazit R, Rossi DJ, Malhotra N, Sylvia K, Kang J, Kreslavsky T, Fletcher A, Elpek K, Bellemarte-Pelletier A, Malhotra D, Turley S.

Nat Immunol. 2013 Jun;14(6):633-43. doi: 10.1038/ni.2587. Epub 2013 Apr 28.

8.

Stage-specific regulation of natural killer cell homeostasis and response against viral infection by microRNA-155.

Zawislak CL, Beaulieu AM, Loeb GB, Karo J, Canner D, Bezman NA, Lanier LL, Rudensky AY, Sun JC.

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6967-72. doi: 10.1073/pnas.1304410110. Epub 2013 Apr 9.

9.

MicroRNA function in NK-cell biology.

Beaulieu AM, Bezman NA, Lee JE, Matloubian M, Sun JC, Lanier LL.

Immunol Rev. 2013 May;253(1):40-52. doi: 10.1111/imr.12045. Review.

10.

Molecular definition of the identity and activation of natural killer cells.

Bezman NA, Kim CC, Sun JC, Min-Oo G, Hendricks DW, Kamimura Y, Best JA, Goldrath AW, Lanier LL; Immunological Genome Project Consortium.

Nat Immunol. 2012 Oct;13(10):1000-9. doi: 10.1038/ni.2395. Epub 2012 Aug 19.

11.

Proinflammatory cytokine signaling required for the generation of natural killer cell memory.

Sun JC, Madera S, Bezman NA, Beilke JN, Kaplan MH, Lanier LL.

J Exp Med. 2012 May 7;209(5):947-54. doi: 10.1084/jem.20111760. Epub 2012 Apr 9.

12.

miR-150 regulates the development of NK and iNKT cells.

Bezman NA, Chakraborty T, Bender T, Lanier LL.

J Exp Med. 2011 Dec 19;208(13):2717-31. doi: 10.1084/jem.20111386. Epub 2011 Nov 28.

13.

Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection.

Sun JC, Beilke JN, Bezman NA, Lanier LL.

J Exp Med. 2011 Feb 14;208(2):357-68. doi: 10.1084/jem.20100479. Epub 2011 Jan 24.

14.

Distinct requirements of microRNAs in NK cell activation, survival, and function.

Bezman NA, Cedars E, Steiner DF, Blelloch R, Hesslein DG, Lanier LL.

J Immunol. 2010 Oct 1;185(7):3835-46. doi: 10.4049/jimmunol.1000980. Epub 2010 Aug 30.

15.

Mislocalization of SLP-76 leads to aberrant inflammatory cytokine and autoantibody production.

Sonnenberg GF, Mangan PR, Bezman NA, Sekiguchi DR, Luning Prak ET, Erikson J, Maltzman JS, Jordan MS, Koretzky GA.

Blood. 2010 Mar 18;115(11):2186-95. doi: 10.1182/blood-2009-08-237438. Epub 2009 Dec 22.

16.

Cutting edge: rescue of pre-TCR but not mature TCR signaling in mice expressing membrane-targeted SLP-76.

Bezman NA, Baker RG, Lenox LE, Jordan MS, Koretzky GA.

J Immunol. 2009 May 1;182(9):5183-7. doi: 10.4049/jimmunol.0802176.

17.

Requirements of SLP76 tyrosines in ITAM and integrin receptor signaling and in platelet function in vivo.

Bezman NA, Lian L, Abrams CS, Brass LF, Kahn ML, Jordan MS, Koretzky GA.

J Exp Med. 2008 Aug 4;205(8):1775-88. doi: 10.1084/jem.20080240. Epub 2008 Jul 28.

18.
19.

Adhesion- and degranulation-promoting adapter protein is required for efficient thymocyte development and selection.

Wu JN, Gheith S, Bezman NA, Liu QH, Fostel LV, Swanson AM, Freedman BD, Koretzky GA, Peterson EJ.

J Immunol. 2006 Jun 1;176(11):6681-9.

20.

In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.

Rathmell WK, Hickey MM, Bezman NA, Chmielecki CA, Carraway NC, Simon MC.

Cancer Res. 2004 Dec 1;64(23):8595-603.

Supplemental Content

Loading ...
Support Center